Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 391

1.

Treatment of Primary Pulmonary Aspergillosis: An Assessment of the Evidence.

Stewart ER, Thompson GR.

J Fungi (Basel). 2016 Sep 8;2(3). pii: E25. doi: 10.3390/jof2030025. Review. Erratum in: J Fungi (Basel). 2016 Nov 04;2(4):.

2.

Pediatric Invasive Aspergillosis.

Wattier RL, Ramirez-Avila L.

J Fungi (Basel). 2016 Jun 13;2(2). pii: E19. doi: 10.3390/jof2020019. Review.

3.

Aspergillosis in Chronic Granulomatous Disease.

King J, Henriet SSV, Warris A.

J Fungi (Basel). 2016 May 26;2(2). pii: E15. doi: 10.3390/jof2020015. Review.

4.
5.

Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections.

Xing Y, Chen L, Feng Y, Zhou Y, Zhai Y, Lu J.

BMC Infect Dis. 2017 Dec 28;17(1):798. doi: 10.1186/s12879-017-2913-8.

6.

Successful treatment of cerebral aspergillosis: case report of a patient with T-cell large granular lymphocytic leukemia (T-LGL).

Turki AT, Rashidi-Alavijeh J, Dürig J, Gerken G, Rath PM, Witzke O.

BMC Infect Dis. 2017 Dec 28;17(1):797. doi: 10.1186/s12879-017-2877-8.

7.

Challenges and Solution of Invasive Aspergillosis in Non-neutropenic Patients: A Review.

Bassetti M, Peghin M, Vena A.

Infect Dis Ther. 2018 Mar;7(1):17-27. doi: 10.1007/s40121-017-0183-9. Epub 2017 Dec 22. Review.

8.

Hyperbaric Oxygen Reduces Aspergillus fumigatus Proliferation In Vitro and Influences In Vivo Disease Outcomes.

Dhingra S, Buckey JC, Cramer RA.

Antimicrob Agents Chemother. 2018 Feb 23;62(3). pii: e01953-17. doi: 10.1128/AAC.01953-17. Print 2018 Mar.

PMID:
29229641
9.

Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO).

Mellinghoff SC, Panse J, Alakel N, Behre G, Buchheidt D, Christopeit M, Hasenkamp J, Kiehl M, Koldehoff M, Krause SW, Lehners N, von Lilienfeld-Toal M, Löhnert AY, Maschmeyer G, Teschner D, Ullmann AJ, Penack O, Ruhnke M, Mayer K, Ostermann H, Wolf HH, Cornely OA.

Ann Hematol. 2018 Feb;97(2):197-207. doi: 10.1007/s00277-017-3196-2. Epub 2017 Dec 7. Review.

10.

Intrinsic short-tailed azole resistance in mucormycetes is due to an evolutionary conserved aminoacid substitution of the lanosterol 14α-demethylase.

Caramalho R, Tyndall JDA, Monk BC, Larentis T, Lass-Flörl C, Lackner M.

Sci Rep. 2017 Nov 21;7(1):15898. doi: 10.1038/s41598-017-16123-9.

11.

An invisible threat: mutation-mediated resistance to triazole drugs in Aspergillus.

Pham CD, Lockhart SR.

Curr Fungal Infect Rep. 2012 Dec;6(4):288-295. doi: 10.1007/s12281-012-0106-x. Epub 2012 Dec 16.

12.

Chitinase Induction Prior to Caspofungin Treatment of Experimental Invasive Aspergillosis in Neutropenic Rats Does Not Enhance Survival.

Refos JM, Vonk AG, Ten Kate MT, Verbrugh HA, Bakker-Woudenberg IAJM, van de Sande WWJ.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e00960-17. doi: 10.1128/AAC.00960-17. Print 2018 Jan.

PMID:
29084744
13.

Pharmacokinetic Modeling of Voriconazole To Develop an Alternative Dosing Regimen in Children.

Gastine S, Lehrnbecher T, Müller C, Farowski F, Bader P, Ullmann-Moskovits J, Cornely OA, Groll AH, Hempel G.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01194-17. doi: 10.1128/AAC.01194-17. Print 2018 Jan.

PMID:
29038273
14.

In Vitro Combination of Isavuconazole with Echinocandins against Azole-Susceptible and -Resistant Aspergillus spp.

Raffetin A, Courbin V, Jullien V, Dannaoui E.

Antimicrob Agents Chemother. 2017 Dec 21;62(1). pii: e01382-17. doi: 10.1128/AAC.01382-17. Print 2018 Jan.

PMID:
29038263
15.

Prevention of Invasive Aspergillosis in High-Risk Patients: Universal Versus Preemptive, Targeted Treatment.

Baddley JW, Apewokin S.

Curr Fungal Infect Rep. 2008 Jun;2:61-68. doi: 10.1007/s12281-008-0010-6. Epub 2008 May 30.

16.

Exposure-Response Relationships for Isavuconazole in Patients with Invasive Aspergillosis and Other Filamentous Fungi.

Desai AV, Kovanda LL, Hope WW, Andes D, Mouton JW, Kowalski DL, Townsend RW, Mujais S, Bonate PL.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e01034-17. doi: 10.1128/AAC.01034-17. Print 2017 Dec.

17.

Voriconazole-refractory invasive aspergillosis.

Park SY, Yoon JA, Kim SH.

Korean J Intern Med. 2017 Sep;32(5):805-812. doi: 10.3904/kjim.2017.109. Epub 2017 Aug 24. Review.

18.

Molecular Diagnosis of Invasive Aspergillosis and Detection of Azole Resistance by a Newly Commercialized PCR Kit.

Dannaoui E, Gabriel F, Gaboyard M, Lagardere G, Audebert L, Quesne G, Godichaud S, Verweij PE, Accoceberry I, Bougnoux ME.

J Clin Microbiol. 2017 Nov;55(11):3210-3218. doi: 10.1128/JCM.01032-17. Epub 2017 Aug 16.

PMID:
28814586
19.

Emerging Infections and Pertinent Infections Related to Travel for Patients with Primary Immunodeficiencies.

Sullivan KE, Bassiri H, Bousfiha AA, Costa-Carvalho BT, Freeman AF, Hagin D, Lau YL, Lionakis MS, Moreira I, Pinto JA, de Moraes-Pinto MI, Rawat A, Reda SM, Reyes SOL, Seppänen M, Tang MLK.

J Clin Immunol. 2017 Oct;37(7):650-692. doi: 10.1007/s10875-017-0426-2. Epub 2017 Aug 7. Review. Erratum in: J Clin Immunol. 2017 Aug 25;:.

PMID:
28786026
20.

Invasive aspergillosis in a patient with end stage renal disease.

Cicek N, Yildiz N, Kadayifci EK, Gokce I, Alpay H.

Med Mycol Case Rep. 2017 Jul 11;18:12-14. doi: 10.1016/j.mmcr.2017.06.006. eCollection 2017 Dec.

Supplemental Content

Support Center